Company* (Symbol)

Product

Description

Indication

Status/Date**

CANCER

Inex Pharmaceuticals Corp. (Canada;TSE:IEX)

INX-3280

Anticancer therapeutic that targets the c-myc gene, believed to be a factor in the uncontrolled cell growth characteristic of tumors

Solid tumors and lymphoma

Filed an investigatonal new drug (IND) application with the Therapeutics Product Programme of Health Canada for approval to begin Phase I trials of INX-3280 in combination with cisplatin (10/13)

Scotia Holdings plc (UK; LSE:SOH)

Foscan

Photodyamic therapeutic

Head and neck cancer

Reported results of Phase Ia trial (10/12)

CARDIOVASCULAR

The Medicines Co.*

Bivalirudin

Anticoagulant therapeutic that directly inhibits thrombin, a key component in blood clot formation and extension

Patients undergoing coronary angioplasty

Received marketing approval in New Zealand (10/25)

NeuroSearch* (Denmark) and Shire Pharmaceuticals Group plc (UK;SHPGY; LSE:SHP.L)

NS1209/SPD 502

Water soluble glutamate AMPA antagonist, thought to be a potential neuroprotectant in the immediate aftermath of ischemic stroke

Acute ischemic stroke

Commenced Phase I trials (10/11)

Dusa Pharmaceuticals Inc. (DUSA)

Levulan

Aminolevulinic acid HC1

Reduction of restenosis following angioplasty of the femoral artery of the leg

Reported results of clinical studies in the UK using Levulan in combination with photodynamic therapy (10/12)

CENTRAL NERVOUS SYSTEM

Neurobiological Technologies Inc.(OTC BB:NTII) and Merz & Co. GmbH & Co. (Germany)

Memantine

An orally deliverable compound thought to be a potential neuroprotective agent

Vascular dementia

Completed two Phase III trials in the UK and France (10/28)

DIABETES

Flamel Technologies S.A. (France; FLMLY)

Basulin

Subcutaneously administered formulation of human insulin

Type 1 and Type 2 diabetes

Received approval from the Medical Ethics Committee in the UK for its protocol for a Phase I trial (10/4)

INFECTION

Gilead Sciences Inc. (GILD)

Adefovir dipivoxil 60 mg

An oral nucleotide reverse transcriptase inhibitor

HIV infection

Marketing authorization application (MAA) accepted by the European Medicines Evaluation Agency (EMEA) (10/25)

Nabi (NABI)

Nabi-HB

Hepatitis B human immune globulin

Hepatitis B

Filed a new drug submission (NDS) with Canadian regulatory authorities (10/21)

MISCELLANEOUS

Biomatrix Inc. (NYSE:BXM)

Synvisc

An elastoviscous hylan therapeutic

Osteoarthritis of the hip

Initiated a clinical trial in France (10/14)

Inflazyme Pharmaceuticals Ltd. (Canada; TSE:IZP) and Hoechst Marion Roussel (the pharmaceutical unit of Hoechst AG; Germany)

IPL576, 092

One of a series of compounds based on a molecule originally isolated from a sea sponge, thought to have significant effect on mediators of inflammation

Asthma

Reported results of Phase Ia trials (10/14)

Nortran Pharmaceuticals Inc. (Canada; VSE: NRT; OTC BB: NTRDF)

CP1

Non-narcotic therapeutic; further details ND

Intractable cough

Completed Phase I trial (10/26)

Vasogen Inc. (Canada; TSE:VAS; OTC BB: VSOGF)

VAS972

Immune modulation therapeutic

Psoriasis

Received approval from Health Canada to proceed with clinical trials (10/19)

Notes:

This chart is intended to provide a monthly update on the clinical and regulatory status of biotech and biotech-related products in development in countries other than the U.S., whether those products are being developed by U.S.-based or non-U.S.-based firms. It covers only those events that were announced in 10/99. It does not cover ongoing clinical trials for which no news was issued that month.

* Indicates a privately held company.

** The dates listed indicate the issue dates of press releases, and are not necessarily the dates on which stated events took place.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange

ND = Not Disclosed